Tags

Type your tag names separated by a space and hit enter

Evidence that Abeta42 plasma levels in presenilin-1 mutation carriers do not allow for prediction of their clinical phenotype.
Neurobiol Dis. 1999 Aug; 6(4):280-7.ND

Abstract

Mutations in the presenilin 1 (PSEN1) gene are an important cause of autosomal dominant Alzheimer's disease (AD). Both in vitro and in vivo experiments showed that PSEN1 mutations increase secretion of amyloid beta42 (Abeta42), the longer and more fibrillogenic isoform of Abeta. We measured secreted Abeta42 in plasma of patients, presymptomatic mutation carriers, and escapees of two extended Belgian early-onset AD families, AD/A and AD/B, with a similar severe phenotype in terms of onset age (mean 35 years), duration of the disease (mean 6.5 years), and pathology. Both families segregate a different missense mutation in PSEN1 located in different parts of the protein: I143T in family AD/A and G384A in family AD/B. A significant increase in Abeta42 concentrations was observed in plasma of mutation carriers in family AD/B, but not in family AD/A. A differential effect of the two PSEN1 mutations on Abeta42 secretion was also detected in conditioned medium of stably transfected HEK293 cells. Both mutations increased Abeta42 secretion significantly; however, the increase was highest for G384A (5.5-fold over wild-type PSEN1), the largest effect observed for missense PSEN1 mutations to date. Although the Abeta42 concentrations measured in vivo and in vitro did not correlate with onset age, a positive correlation was obtained with age in the presymptomatic mutation carriers and a negative correlation with duration of disease in the patients. Our data obtained for PSEN1 mutation carriers suggest that measuring Abeta42 concentrations in plasma will be informative as a diagnostic marker in a limited number of cases.

Authors+Show Affiliations

Flanders Interunivesity Institute for Biotechnology (VIB) and Born Bunge Foundation, Department of Biochemistry, University of Antwerp, Antwerpen, Belgium.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10448055

Citation

De Jonghe, C, et al. "Evidence That Abeta42 Plasma Levels in Presenilin-1 Mutation Carriers Do Not Allow for Prediction of Their Clinical Phenotype." Neurobiology of Disease, vol. 6, no. 4, 1999, pp. 280-7.
De Jonghe C, Cras P, Vanderstichele H, et al. Evidence that Abeta42 plasma levels in presenilin-1 mutation carriers do not allow for prediction of their clinical phenotype. Neurobiol Dis. 1999;6(4):280-7.
De Jonghe, C., Cras, P., Vanderstichele, H., Cruts, M., Vanderhoeven, I., Smouts, I., Vanmechelen, E., Martin, J. J., Hendriks, L., & Van Broeckhoven, C. (1999). Evidence that Abeta42 plasma levels in presenilin-1 mutation carriers do not allow for prediction of their clinical phenotype. Neurobiology of Disease, 6(4), 280-7.
De Jonghe C, et al. Evidence That Abeta42 Plasma Levels in Presenilin-1 Mutation Carriers Do Not Allow for Prediction of Their Clinical Phenotype. Neurobiol Dis. 1999;6(4):280-7. PubMed PMID: 10448055.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evidence that Abeta42 plasma levels in presenilin-1 mutation carriers do not allow for prediction of their clinical phenotype. AU - De Jonghe,C, AU - Cras,P, AU - Vanderstichele,H, AU - Cruts,M, AU - Vanderhoeven,I, AU - Smouts,I, AU - Vanmechelen,E, AU - Martin,J J, AU - Hendriks,L, AU - Van Broeckhoven,C, PY - 1999/8/17/pubmed PY - 1999/8/17/medline PY - 1999/8/17/entrez SP - 280 EP - 7 JF - Neurobiology of disease JO - Neurobiol Dis VL - 6 IS - 4 N2 - Mutations in the presenilin 1 (PSEN1) gene are an important cause of autosomal dominant Alzheimer's disease (AD). Both in vitro and in vivo experiments showed that PSEN1 mutations increase secretion of amyloid beta42 (Abeta42), the longer and more fibrillogenic isoform of Abeta. We measured secreted Abeta42 in plasma of patients, presymptomatic mutation carriers, and escapees of two extended Belgian early-onset AD families, AD/A and AD/B, with a similar severe phenotype in terms of onset age (mean 35 years), duration of the disease (mean 6.5 years), and pathology. Both families segregate a different missense mutation in PSEN1 located in different parts of the protein: I143T in family AD/A and G384A in family AD/B. A significant increase in Abeta42 concentrations was observed in plasma of mutation carriers in family AD/B, but not in family AD/A. A differential effect of the two PSEN1 mutations on Abeta42 secretion was also detected in conditioned medium of stably transfected HEK293 cells. Both mutations increased Abeta42 secretion significantly; however, the increase was highest for G384A (5.5-fold over wild-type PSEN1), the largest effect observed for missense PSEN1 mutations to date. Although the Abeta42 concentrations measured in vivo and in vitro did not correlate with onset age, a positive correlation was obtained with age in the presymptomatic mutation carriers and a negative correlation with duration of disease in the patients. Our data obtained for PSEN1 mutation carriers suggest that measuring Abeta42 concentrations in plasma will be informative as a diagnostic marker in a limited number of cases. SN - 0969-9961 UR - https://www.unboundmedicine.com/medline/citation/10448055/Evidence_that_Abeta42_plasma_levels_in_presenilin_1_mutation_carriers_do_not_allow_for_prediction_of_their_clinical_phenotype_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0969-9961(99)90247-4 DB - PRIME DP - Unbound Medicine ER -